Ferritin Light Chain (FTL) is the light-chain subunit of ferritin, the major intracellular iron storage protein. Ferritin assembles into a hollow 24-subunit nanocage (comprising FTH heavy chains and FTL light chains in variable ratios) that can store up to 4,500 iron atoms in a soluble, non-toxic form . FTL is critical for iron detoxification, oxidative stress prevention, and the regulation of cellular iron homeostasis. Mutations in FTL cause neuroferritinopathy (also called neurodegeneration with brain iron accumulation type 2, NBIA2), an autosomal dominant movement disorder with iron accumulation in the basal ganglia. Beyond rare genetic causes, FTL/ferritin dysregulation is consistently observed in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, making ferritin an important biomarker and therapeutic target.
| Ferritin Light Chain Protein |
|---|
| Protein Name | Ferritin Light Chain (FTL) |
| Gene | [FTL](/genes/ftl) |
| UniProt ID | [P02792](https://www.uniprot.org/uniprot/P02792) |
| PDB IDs | 2FHL, 3CA0 |
| Molecular Weight | 20 kDa (monomer) |
| Subcellular Localization | Cytoplasm, lysosomes, mitochondria |
| Protein Family | Ferritin family (multimeric iron storage) |
Ferritin is a 480 kDa protein complex formed by 24 subunits arranged in a hollow spherical shell:
- Heavy chain (FTH1/FTH): 21 kDa subunit with robust ferroxidase activity (converts Fe²⁺ to Fe³⁺). Essential for iron uptake.
- Light chain (FTL): 20 kDa subunit with slower ferroxidase activity but greater iron nucleation capacity. Provides structural stability and optimizes iron storage.
Heteropolymer composition: Human ferritin typically has ~20 FTH subunits and ~4 FTL subunits per 24-mer (ratio varies by tissue). Brain ferritin has higher FTH content.
- Ions at subunit interfaces: FTL contributes hydrophobic residues at subunit interfaces that stabilize the cage
- Iron nucleation site: FTL has residues (Glu56, Glu57) that promote iron phosphate mineral formation inside the cavity
- C-terminal residues: Important for protein-protein interactions and targeting to specific cellular compartments
¶ Assembly and Targeting
- Cytosolic ferritin: Assembles in the cytoplasm as a stable 24-mer
- Mitochondrial ferritin (FTMT): A separate iron-storage protein in mitochondria, structurally similar but independently encoded
- Targeting to lysosomes: Ferritin can be targeted for lysosomal degradation via ferritinophagy (NCOA4-mediated)
¶ Iron Storage and Detoxification
Ferritin is the primary intracellular iron storage mechanism:
- Fe²⁺ entry: Iron enters the ferritin shell through channels at 3-fold symmetry axes
- Ferroxidase reaction (FTH): FTH converts Fe²⁺ to Fe³⁺ at the ferroxidase site, preventing Fenton chemistry
- Iron nucleation (FTL): Fe³⁺ is transferred to the interior cavity where it forms a mineral (ferrihydrite)
- Storage: Up to 4,500 iron atoms stored as ferrihydrite (Fe₂O₃·H₂O)
In the brain, ferritin performs critical protective roles:
- Prevents ferroptosis: Iron-dependent, lipid-peroxidation-driven cell death is suppressed by adequate ferritin stores
- Antioxidant defense: By sequestering iron, ferritin prevents hydroxyl radical (·OH) formation via Fenton chemistry
- Oligodendrocyte function: Myelin-producing oligodendrocytes have very high ferritin content — iron is required for myelin synthesis
- Neuronal iron homeostasis: Neurons express ferritin in response to oxidative stress and iron loading
Ferritin degradation via autophagy (ferritinophagy) is a key regulatory mechanism:
- NCOA4: The selective autophagy receptor that delivers ferritin to lysosomes
- Iron release: Ferritinophagy releases stored iron, regulating the labile iron pool (LIP)
- Ferroptosis regulation: NCOA4 knockdown prevents ferritinophagy and reduces ferroptosis sensitivity
- Neurodegeneration: Dysregulated ferritinophagy contributes to iron accumulation and cell death in AD and PD
Dominant mutations in FTL (notably the 460dupA insertion) cause neuroferritinopathy [@kono2013; @soo2017]:
Pathogenic mechanism:
- Frameshift mutation: 460dupA shifts the reading frame, adding 53 aberrant C-terminal residues
- Loss of ferroxidase activity: Mutant FTL incorporates into ferritin shells, disrupting iron oxidation
- Iron release from ferritin: Abnormal ferritin releases iron prematurely into the cytoplasm
- Aggregate formation: Mutant FTL and iron accumulate in neurons, forming basophilic inclusions and Lewy-like bodies
Clinical features:
- Adult onset: Typically 30-50 years old
- Movement disorder: Chorea, dystonia, parkinsonism, spasticity
- Cognitive decline: Variable, progressive
- Psychiatric symptoms: Personality changes, depression
- Iron deposition: MRI shows iron accumulation in globus pallidus, putamen, red nucleus, and dentate nucleus
- Histopathology: Ferritin-positive inclusions, gliosis, neuronal loss
Treatment:
- Iron chelation: Deferiprone, deferoxamine — may slow progression
- Antioxidants: CoQ10, vitamin E — protect against iron-mediated oxidative damage
- Ferroptosis inhibition: Liproxstatin-1 and related compounds in research settings
Ferritin is consistently altered in AD :
- Elevated brain ferritin: FTL and FTH are upregulated in AD brain tissue, particularly in microglia surrounding amyloid plaques
- Iron accumulation in neurons: Neuronal ferritin increases as a compensatory response to iron dysregulation
- Correlation with pathology: Brain ferritin levels correlate with amyloid plaque burden and cognitive decline
- CSF ferritin: Elevated CSF ferritin is a marker of neuronal iron dysregulation and neuroinflammation
- Mechanistic links: Iron promotes Aβ aggregation, tau hyperphosphorylation, and oxidative stress — ferritin is a protective response
In PD, iron accumulation in the substantia nigra is a well-established finding :
- Iron elevation in SNc: Postmortem studies consistently show elevated iron in PD substantia nigra pars compacta
- Ferritin upregulation: FTL and FTH are induced in dopaminergic neurons as a stress response
- Microglial ferritin: Activated microglia show high ferritin content — iron handling by glia is dysregulated
- Locus coeruleus: Iron accumulation is also seen in the noradrenergic nucleus
- Clinical correlation: Higher substantia nigra iron (measured by MRI) correlates with more severe PD symptoms
- Ferroptosis link: PD neurons may undergo ferroptosis — ferritin preservation is neuroprotective
- Demyelination and iron: Myelin loss releases iron, which catalyzes oxidative damage
- Oligodendrocyte vulnerability: Iron-loaded oligodendrocytes are particularly susceptible to death
- Chronic lesion iron: Active MS lesions show iron deposition at the edges
¶ ALS and Other Disorders
- FTL inclusions found in some ALS cases
- Huntington's disease and Friedreich's ataxia show altered iron metabolism
| Drug |
Mechanism |
Clinical Use |
Notes |
| Deferoxamine |
Fe³⁺ chelation |
NBIA, PD (trials) |
Poor BBB penetration; injectable |
| Deferasirox |
Oral Fe³⁺ chelation |
NBIA, PD (trials) |
Better compliance; CNS penetration limited |
| Deferiprone |
Fe²⁺ chelation |
NBIA2, thalassemia |
Crosses BBB; proven iron reduction in PD |
Deferiprone has shown promise in PD trials (FAIR-II) — it reduces substantia nigra iron and may slow motor progression.
- Ferrostatin-1: Lipid antioxidant that prevents ferroptosis by scavenging lipid peroxyl radicals
- Liproxstatin-1: More potent analog; protects in animal models of neurodegeneration
- GPX4 upregulation: Glutathione peroxidase 4 prevents lipid peroxidation — iron chelation + GPX4 activation may be synergistic
- NCOA4 targeting: Modulating ferritinophagy to control iron release
- Ferritin overexpression: AAV-mediated ferritin delivery to increase iron storage capacity
- Iron-sulfur cluster repair: Supporting Fe-S cluster biogenesis reduces labile iron
- CSF ferritin: Non-invasive marker of brain iron dysregulation
- MRI R2 mapping*: Quantifies iron content in specific brain regions
- SWI imaging: Susceptibility-weighted imaging detects iron deposits
| Partner |
Interaction Type |
Functional Consequence |
| FTH (ferritin heavy chain) |
Co-assembly |
Forms the 24-mer ferritin nanocage |
| NCOA4 |
Autophagy receptor |
Ferritinophagy and iron recycling |
| IRP1/IRP2 |
Iron regulatory proteins |
Control FTL mRNA translation via IREs |
| LIP (labile iron pool) |
Equilibrium |
Ferritin stores buffer free iron |
| DMT1 |
Iron transporter |
Iron import into cytoplasm |
| Ferroportin (SLC40A1) |
Iron export |
Ferritin + ferroportin coordinate iron efflux |
| Ceruloplasmin (CP) |
Cooperativity |
CP oxidizes Fe²⁺ for export; coordinated with ferritin |
| Transferrin receptor |
Iron import |
Tf-Fe³⁺ → endosome → DMT1 → cytoplasm |